Lippoldt Darin

SEC source: 0001504783-26-000019 · wk-form4_1789506394.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,793

F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

SEC source: 0001504783-26-000019 · wk-form4_1789506394.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,212

F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

SEC source: 0001504783-26-000017 · wk-form4_1783974426.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,965

Underlying: Common Stock · 10,000 shares

Expires 2028-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

SEC source: 0001504783-26-000017 · wk-form4_1783974426.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,729

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $179.50 to $179.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001504783-26-000017 · wk-form4_1783974426.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · derivative · entry 9

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,965

Underlying: Common Stock · 1,690 shares

Expires 2028-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · derivative · entry 8

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,655

Underlying: Common Stock · 8,110 shares

Expires 2028-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · nonDerivative · entry 6

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,729

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.58 to $170.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · nonDerivative · entry 5

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · nonDerivative · entry 4

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,729

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.57 to $170.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · nonDerivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · derivative · entry 7

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,765

Underlying: Common Stock · 200 shares

Expires 2028-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,729

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.56 to $169.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001504783-26-000015 · wk-form4_1782852730.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,929

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 14

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,124

Underlying: Common Stock · 6,124 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 13

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,909

Underlying: Common Stock · 34,909 shares

Expires 2036-02-13

F8 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 12

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,083

Underlying: Common Stock · 2,083 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award.

F7 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 11

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,036

Underlying: Common Stock · 2,017 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,017 shares on February 13, 2025, vested as to 2,017 shares on February 13, 2026, and will vest as to 2,018 shares on February 13, 2027, and 2,018 shares on February 13, 2028, subject to the terms and conditions of the award.

F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,017 shares on February 13, 2025, vested as to 2,017 shares on February 13, 2026, and will vest as to 2,018 shares on February 13, 2027, and 2,018 shares on February 13, 2028, subject to the terms and conditions of the award.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 9

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,729

F3 · shares: Represents gift/charitable contributions effective February 13, 2026. This is not a market transaction; thus no price has been reported. No value was received for the gifted shares.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 8

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,094

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 7

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,472

F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 6

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,504

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 5

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,628

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 4

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,545

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,634

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 10

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,377

Underlying: Common Stock · 1,792 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,792 shares on February 12, 2026, and will vest as to 1,792 shares on February 12, 2027, 1,792 shares on February 12, 2028, and 1,792 shares on February 12, 2029, subject to the terms and conditions of the award.

F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,792 shares on February 12, 2026, and will vest as to 1,792 shares on February 12, 2027, 1,792 shares on February 12, 2028, and 1,792 shares on February 12, 2029, subject to the terms and conditions of the award.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,617

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

SEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,584

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000007 · wk-form4_1770159705.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,373 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,373 shares on January 31, 2023, vested as to 2,373 shares on January 31, 2024, vested as to 2,373 shares on January 31, 2025, and vested as to 2,373 shares on January 31, 2026, subject to the terms and conditions of the award.

F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,373 shares on January 31, 2023, vested as to 2,373 shares on January 31, 2024, vested as to 2,373 shares on January 31, 2025, and vested as to 2,373 shares on January 31, 2026, subject to the terms and conditions of the award.

SEC source: 0001504783-26-000007 · wk-form4_1770159705.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,792

F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.

SEC source: 0001504783-26-000007 · wk-form4_1770159705.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-26-000004 · wk-form4_1768252668.xml · derivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,349 shares

Expires 2026-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option was granted February 5, 2016 and vested monthly over four years. These options were due to expire on February 5, 2026.

SEC source: 0001504783-26-000004 · wk-form4_1768252668.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001504783-25-000006 · wk-form4_1765375469.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,376 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted February 6, 2017 and vested monthly over four years. These options were due to expire on February 6, 2027.

SEC source: 0001504783-25-000006 · wk-form4_1765375469.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,405

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $159.50 to $159.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001504783-25-000006 · wk-form4_1765375469.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · derivative · entry 9

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,053

Underlying: Common Stock · 2,017 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F9 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,017 shares on February 13, 2025, and will vest as to 2,017 shares on February 13, 2026, 2,018 shares on February 13, 2027, and 2,018 shares on February 13, 2028, subject to the terms and conditions of the award.

F9 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,017 shares on February 13, 2025, and will vest as to 2,017 shares on February 13, 2026, 2,018 shares on February 13, 2027, and 2,018 shares on February 13, 2028, subject to the terms and conditions of the award.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · derivative · entry 8

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,166

Underlying: Common Stock · 2,083 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F8 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, and will vest as to 2,083 shares on February 13, 2026, and 2,083 shares on February 13, 2027, subject to the terms and conditions of the award.

F8 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, and will vest as to 2,083 shares on February 13, 2026, and 2,083 shares on February 13, 2027, subject to the terms and conditions of the award.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · nonDerivative · entry 5

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,405

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $118.38. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · nonDerivative · entry 4

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · nonDerivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,474

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,572

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · derivative · entry 7

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,169

Underlying: Common Stock · 7,169 shares

Expires not disclosed

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.

F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · derivative · entry 6

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,252

Underlying: Common Stock · 38,252 shares

Expires 2035-02-12

F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

SEC source: 0000914475-25-000065 · wk-form4_1739575564.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,489

SEC source: 0000914475-25-000050 · wk-form4_1739404191.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,679

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.07 to $123.53 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-25-000050 · wk-form4_1739404191.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,727 shares on February 8, 2022, vested as to 1,727 shares on February 8, 2023, vested as to 1,727 shares on February 8, 2024, and vested as to 1,727 shares on February 8, 2025, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,727 shares on February 8, 2022, vested as to 1,727 shares on February 8, 2023, vested as to 1,727 shares on February 8, 2024, and vested as to 1,727 shares on February 8, 2025, subject to the terms and conditions of the award.

SEC source: 0000914475-25-000050 · wk-form4_1739404191.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,590

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-25-000026 · wk-form4_1738709367.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,373

Underlying: Common Stock · 2,373 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,373 shares on January 31, 2023, vested as to 2,373 shares on January 31, 2024, vested as to 2,373 shares on January 31, 2025, and will vest as to 2,373 shares on January 31, 2026, subject to the terms and conditions of the award.

F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,373 shares on January 31, 2023, vested as to 2,373 shares on January 31, 2024, vested as to 2,373 shares on January 31, 2025, and will vest as to 2,373 shares on January 31, 2026, subject to the terms and conditions of the award.

SEC source: 0000914475-25-000026 · wk-form4_1738709367.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,863

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.